Benchmark Holdings (BMK)

Sector:

Pharma and Biotech

Index:

FTSE AIM 100

48.00p
   
  • Change Today:
      3.50p
  • 52 Week High: 64.00p
  • 52 Week Low: 40.00p
  • Currency: UK Pounds
  • Shares Issued: 703.96m
  • Volume: 267,007
  • Market Cap: £337.90m

Benchmark clears regulatory milestone for sea lice treatment

By Josh White

Date: Friday 16 Apr 2021

LONDON (ShareCast) - (Sharecast News) - Benchmark announced on Friday that the maximum residue limit (MRL) for its novel sea lice treatment 'BMK08' had been ratified under European law.
The AIM-traded firm said the MRL confirmed the safety of its sea lice solution for consumers, and represented a "significant" milestone in the regulatory approval process towards the expected commercial launch of BMK08 and 'CleanTreat' in Norway.

It said the commercial launch remained subject to the grant of a marketing authorisation in the country.

Benchmark described BMK08 and CleanTreat as a 'transformational solution' addressing the biggest biological challenge in salmon farming.

The MRL ratification was said to be the culmination of almost a decade of research and development, a rigorous trial programme and substantial capital investment by Benchmark.

"The ratification of the MRL is a further stepping stone towards commercialisation following the announcement of our first customer agreements for CleanTreat announced in March," said chief executive officer Trond Williksen.

"Sea lice continues to be the biggest biological challenge for salmon producers and Benchmark's novel solution addresses this challenge in a sustainable way both in terms of animal welfare and environmental impact."

At 1501 BST, shares in Benchmark Holdings were up 8.03% at 65.9p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

BMK Market Data

Currency UK Pounds
Share Price 48.00p
Change Today 3.50p
% Change 7.87 %
52 Week High 64.00p
52 Week Low 40.00p
Volume 267,007
Shares Issued 703.96m
Market Cap £337.90m

BMK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
13.46% below the market average13.46% below the market average13.46% below the market average13.46% below the market average13.46% below the market average
45.45% above the sector average45.45% above the sector average45.45% above the sector average45.45% above the sector average45.45% above the sector average
Price Trend
2.87% below the market average2.87% below the market average2.87% below the market average2.87% below the market average2.87% below the market average
49.21% above the sector average49.21% above the sector average49.21% above the sector average49.21% above the sector average49.21% above the sector average
Income Not Available
Growth
4.68% below the market average4.68% below the market average4.68% below the market average4.68% below the market average4.68% below the market average
60% below the sector average60% below the sector average60% below the sector average60% below the sector average60% below the sector average

What The Brokers Say

Strong Buy 3
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 3
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

BMK Dividends

No dividends found

Trades for 20-May-2022

Time Volume / Share Price
17:08 23,000 @ 48.00p
16:35 622 @ 48.00p
16:15 1,000 @ 48.00p
16:14 3,658 @ 50.00p
16:12 5,000 @ 48.25p

BMK Key Personnel

CFO Septima Maguire
CEO Trond Williksen

Top of Page